News

Important news about our latest
developments in science & medicine.

Background Image

Press Releases

  • Mitsubishi Tanabe Pharma America Announces Collaborative Study to Identify and Measure Biomarkers in People With ALS

    Findings Will Help Further Understanding...

    Read more
  • Mitsubishi Tanabe Pharma Group Companies to Present New Data on Investigational Oral Formulation at MNDA

    Initial Study Results Show A Single Oral...

    Read more
  • Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of ALS Treatment

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Announces over 3,000 Patients in the U.S. With ALS Have Been Treated With RADICAVA® (Edaravone) in the Last Year

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Marks One-year Anniversary of Only FDA-approved ALS Treatment Option in the Last 20 Years

    Since Becoming Available, More Than 2,500...

    Read more
  • Mitsubishi Tanabe Pharma America Announces ALS Presentations at American Academy of Neurology Annual Meeting

    Analysis of Patient U.S. Health Claims...

    Read more
  • Mitsubishi Tanabe Pharma America Initiates Independent Research Program for RADICAVA® (edaravone)

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Announces Addition of RADICAVA® (edaravone) to U.S. Department of Veterans Affairs National Formulary

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Announces 1,000 People with ALS Have Received FDA-Approved Treatment Option in First Three Months Available

    Searchlight SupportTM Staff...

    Read more
  • Mitsubishi Tanabe Pharma America Signs Agreement with Option Care For National Home Infusion Services

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • First FDA-approved Treatment for ALS in 22 Years Now Available in U.S.

    RADICAVATM (edaravone)...

    Read more
  • MT Pharma America Begins Patient Insurance Benefits Investigation Process in Advance of Availability of RADICAVATM (Edaravone)

    MT Pharma America, Inc. today announced...

    Read more
  • Mitsubishi Tanabe Pharma America Presents 12-Month RADICAVATM (Edaravone) and Amyotrophic Lateral Sclerosis Data at the European Network for the Cure of ALS (ENCALS) Annual Meeting

    MT Pharma America, Inc. (MTPA) today...

    Read more
  • MT Pharma America Announces FDA Approval of RADICAVATM (Edaravone), the First New Treatment Option for ALS in More Than 20 Years

    First FDA-approved ALS treatment option in...

    Read more
  • 12-month Edaravone Clinical Study Data in ALS Presented at the 27th International Symposium on ALS/MND

    Mitsubishi Tanabe Pharma Corporation (Head...

    Read more
  • FDA Accepts Mitsubishi Tanabe Pharma’s NDA Filing for Edaravone to Treat ALS

    Edaravone may be the first ALS treatment...

    Read more
  • Mitsubishi Tanabe Pharma Corporation Presents Edaravone Clinical Trial Data in ALS at 2016 American Academy of Neurology Annual Meeting

    Mitsubishi Tanabe Pharma Corporation...

    Read more
  • Mitsubishi Tanabe Pharma America to Showcase ALS Research at 29th International Symposium on ALS/MND in Glasgow

    Presentations Highlight Commitment to...

    Read more
  • Mitsubishi Tanabe Pharma America’s ALSO USTM Initiative Begins Accepting Artistic Submissions from Teens Impacted by ALS

    Program to Showcase Original, Teen-Created...

    Read more
  • Mitsubishi Tanabe Pharma America Appoints Joseph Scalia As Vice President of Sales and Marketing

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America to Present Data on Radicava® (Edaravone) at the European Network for the Cure of ALS (ENCALS) Annual Meeting

    Assessments of RADICAVA Clinical Trial...

    Read more
  • Mitsubishi Tanabe Pharma America and Neuroderm Announce Parkinson’s Disease Presentations at American Academy of Neurology Annual Meeting

    Phase 2 Data on Investigational...

    Read more
  • Health Canada Accepts Mitsubishi Tanabe Pharma Corporation’s NDS Filing for Edaravone to Treat ALS, Grants Priority Review

    Mitsubishi Tanabe Pharma Canada Launched...

    Read more
  • Mitsubishi Tanabe Pharma America to Present Data on RADICAVA® (Edaravone) At 28th International Symposium on ALS/MND in Boston

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Expands Executive Leadership Team, Names Kevin O’Brien as Vice President of Market Access

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Comprehensive Edaravone Clinical Program Data Published as Supplement to Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • MTPA Perspective Regarding Medicare Coverage

    As an FDA-approved therapy, RADICAVATM...

    Read more
  • MT Pharma America Announces Corporate Name Change to Mitsubishi Tanabe Pharma America

    MT Pharma America, Inc. today announced...

    Read more
  • Mitsubishi Tanabe Pharma America Enrolls More Than 700 Sites of Care in Newly Created National Infusion Center Directory for ALS Patients

    MT Pharma America, Inc. today announced...

    Read more
  • RADICAVATM (edaravone) Prescribing Information

    ...

    Read more
  • MT Pharma America to Present Data on Investigational Edaravone and Amyotrophic Lateral Sclerosis at the 2017 American Academy of Neurology Annual Meeting

    MT Pharma America, Inc. (MTPA) today...

    Read more
  • The ALS Association Welcomes MT Pharma America as National Corporate Sponsor

    The ALS Association is pleased to announce...

    Read more
  • Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United States

    Mitsubishi Tanabe Pharma Corporation...

    Read more
  • Mitsubishi Tanabe Pharma America Announces Collaborative Study to Identify and Measure Biomarkers in People With ALS

    Findings Will Help Further Understanding...

    Read more
  • Mitsubishi Tanabe Pharma America to Showcase ALS Research at 29th International Symposium on ALS/MND in Glasgow

    Presentations Highlight Commitment to...

    Read more
  • Mitsubishi Tanabe Pharma Group Companies to Present New Data on Investigational Oral Formulation at MNDA

    Initial Study Results Show A Single Oral...

    Read more
  • Mitsubishi Tanabe Pharma America’s ALSO USTM Initiative Begins Accepting Artistic Submissions from Teens Impacted by ALS

    Program to Showcase Original, Teen-Created...

    Read more
  • Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of ALS Treatment

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Appoints Joseph Scalia As Vice President of Sales and Marketing

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Announces over 3,000 Patients in the U.S. With ALS Have Been Treated With RADICAVA® (Edaravone) in the Last Year

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America to Present Data on Radicava® (Edaravone) at the European Network for the Cure of ALS (ENCALS) Annual Meeting

    Assessments of RADICAVA Clinical Trial...

    Read more
  • Mitsubishi Tanabe Pharma America Marks One-year Anniversary of Only FDA-approved ALS Treatment Option in the Last 20 Years

    Since Becoming Available, More Than 2,500...

    Read more
  • Mitsubishi Tanabe Pharma America and Neuroderm Announce Parkinson’s Disease Presentations at American Academy of Neurology Annual Meeting

    Phase 2 Data on Investigational...

    Read more
  • Mitsubishi Tanabe Pharma America Announces ALS Presentations at American Academy of Neurology Annual Meeting

    Analysis of Patient U.S. Health Claims...

    Read more
  • Health Canada Accepts Mitsubishi Tanabe Pharma Corporation’s NDS Filing for Edaravone to Treat ALS, Grants Priority Review

    Mitsubishi Tanabe Pharma Canada Launched...

    Read more
  • Mitsubishi Tanabe Pharma America Initiates Independent Research Program for RADICAVA® (edaravone)

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America to Present Data on RADICAVA® (Edaravone) At 28th International Symposium on ALS/MND in Boston

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Announces Addition of RADICAVA® (edaravone) to U.S. Department of Veterans Affairs National Formulary

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Expands Executive Leadership Team, Names Kevin O’Brien as Vice President of Market Access

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Announces 1,000 People with ALS Have Received FDA-Approved Treatment Option in First Three Months Available

    Searchlight SupportTM Staff...

    Read more
  • Comprehensive Edaravone Clinical Program Data Published as Supplement to Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Signs Agreement with Option Care For National Home Infusion Services

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • MTPA Perspective Regarding Medicare Coverage

    As an FDA-approved therapy, RADICAVATM...

    Read more
  • First FDA-approved Treatment for ALS in 22 Years Now Available in U.S.

    RADICAVATM (edaravone)...

    Read more
  • MT Pharma America Announces Corporate Name Change to Mitsubishi Tanabe Pharma America

    MT Pharma America, Inc. today announced...

    Read more
  • MT Pharma America Begins Patient Insurance Benefits Investigation Process in Advance of Availability of RADICAVATM (Edaravone)

    MT Pharma America, Inc. today announced...

    Read more
  • Mitsubishi Tanabe Pharma America Enrolls More Than 700 Sites of Care in Newly Created National Infusion Center Directory for ALS Patients

    MT Pharma America, Inc. today announced...

    Read more
  • Mitsubishi Tanabe Pharma America Presents 12-Month RADICAVATM (Edaravone) and Amyotrophic Lateral Sclerosis Data at the European Network for the Cure of ALS (ENCALS) Annual Meeting

    MT Pharma America, Inc. (MTPA) today...

    Read more
  • RADICAVATM (edaravone) Prescribing Information

    ...

    Read more
  • MT Pharma America Announces FDA Approval of RADICAVATM (Edaravone), the First New Treatment Option for ALS in More Than 20 Years

    First FDA-approved ALS treatment option in...

    Read more
  • MT Pharma America to Present Data on Investigational Edaravone and Amyotrophic Lateral Sclerosis at the 2017 American Academy of Neurology Annual Meeting

    MT Pharma America, Inc. (MTPA) today...

    Read more
  • 12-month Edaravone Clinical Study Data in ALS Presented at the 27th International Symposium on ALS/MND

    Mitsubishi Tanabe Pharma Corporation (Head...

    Read more
  • The ALS Association Welcomes MT Pharma America as National Corporate Sponsor

    The ALS Association is pleased to announce...

    Read more
  • FDA Accepts Mitsubishi Tanabe Pharma’s NDA Filing for Edaravone to Treat ALS

    Edaravone may be the first ALS treatment...

    Read more
  • Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United States

    Mitsubishi Tanabe Pharma Corporation...

    Read more
  • Mitsubishi Tanabe Pharma Corporation Presents Edaravone Clinical Trial Data in ALS at 2016 American Academy of Neurology Annual Meeting

    Mitsubishi Tanabe Pharma Corporation...

    Read more

Load More

Scientific Exchange

  • Dec
    MNDA Motor Neuron Disease Association Symposium
    December 6 to December 9 Glasgow, Scotland